Market Cap 6.87B
Revenue (ttm) 8.55M
Net Income (ttm) -182.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,138.25%
Debt to Equity Ratio 0.00
Volume 208,900
Avg Vol 1,221,406
Day's Range N/A - N/A
Shares Out 25.01M
Stochastic %K 51%
Beta 2.95
Analysts Strong Sell
Price Target $419.13

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-ty...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 300 8460
Address:
99 High Street, 30th Floor, Boston, United States
Quantumup
Quantumup Dec. 26 at 1:31 PM
Stifel reit $XENE Buy-$60/said—We're reiterating our Buy rating on XENE on the back of BHVN's Kv7 failing in MDD. $BHVN $PRAX $JAZZ NBIX $RAPP Stifel added: Bottom line: we continue to believe that there's limited evidence suggesting that BHVN's Kv7 compound (BHV-7000) will be as efficacious as XEN1101. To be fair, MDD itself is risky and not yet de-risked for the Kv7 class -- it's still possible that Kv7s (including BHV-7000) end up having more limited utility in neuropsych, even if the mechanism is de-risked in FOS/epilepsy. That said, for BHV-7000 specifically, we continue to believe that to date, there's limited evidence of meaningful pharmacodynamic effect in the CNS: (1) we view prior EEG data as uninterpretable -- at the very least, less relevant to efficacy on actual seizures, and (2) we also believe the very clean AE/safety data of BHV-7000 raises the question of whether the drug is behaving like a potent anti-epileptic in the brain; we are skeptical of the GABA-selectivity thesis.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 10:26 AM
🔎 $PRAX Options Scan Update (04:26 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 1:46 AM
Enter: $PRAX Calls Strike Price: $280 Expiry Date: JAN 16 2026 Buy in Price: $18.90 - $22.00 Sell Price: $50.60 Profit : +130% (Turn every $1 into $2.30) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 8:27 PM
$PRAX RSI: 79.68, MACD: 25.8263 Vol: 39.04, MA20: 244.47, MA50: 204.41 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:14 PM
Actionable Trade Alert for $PRAX: Market Context: $PRAX is currently trading at $274.76, with a strong RSI of 79.68, indicating overbought conditions. The price is significantly above both the 30-day MA of 223.92 and the 50-day MA of 204.41, suggesting upward momentum but caution due to potential pullbacks. Directional Bias: Given the high RSI and proximity to the 60D high of 286.5, we anticipate a possible retracement before further upward movement. The 60D low of 50.31 provides a broad range for potential price action. Trade Plan: - Suggested Entry: $274.76 - Stop Loss: $250.00 (approximately 9% below entry) - Take Profit Targets: 1. $290.00 (5.5% gain) 2. $320.00 (16.4% gain) 3. $321.00 (17% gain) This plan allows for a strategic entry while managing risk effectively. Monitor RSI for any signs of reversal before entering. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
UnicornUptick
UnicornUptick Dec. 25 at 10:53 AM
$PRAX Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Execution reliability across quarters will determine whether confidence can compound. Any disconnect between guidance and results will be magnified by sentiment. Risk remains manageable if management converts plans into consistent outputs.
0 · Reply
NowakYandrey
NowakYandrey Dec. 24 at 5:13 PM
Here are my current positions: $SNDK $PRAX Looking great heading into Christmas
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 3:56 PM
Enter: $PRAX Calls Strike Price: $290 Expiry Date: JAN 16 2026 Buy in Price: $13.62 - $14.30 Sell Price: $20.84 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
R84877P
R84877P Dec. 22 at 10:39 PM
$PRAX Done and done ✅
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 22 at 10:10 PM
Enter: $PRAX Calls Strike Price: $280 Expiry Date: JAN 16 2026 Buy in Price: $17.81 - $19.40 Sell Price: $37.58 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on PRAX
What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 12:02 PM EDT - 2 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?


Quantumup
Quantumup Dec. 26 at 1:31 PM
Stifel reit $XENE Buy-$60/said—We're reiterating our Buy rating on XENE on the back of BHVN's Kv7 failing in MDD. $BHVN $PRAX $JAZZ NBIX $RAPP Stifel added: Bottom line: we continue to believe that there's limited evidence suggesting that BHVN's Kv7 compound (BHV-7000) will be as efficacious as XEN1101. To be fair, MDD itself is risky and not yet de-risked for the Kv7 class -- it's still possible that Kv7s (including BHV-7000) end up having more limited utility in neuropsych, even if the mechanism is de-risked in FOS/epilepsy. That said, for BHV-7000 specifically, we continue to believe that to date, there's limited evidence of meaningful pharmacodynamic effect in the CNS: (1) we view prior EEG data as uninterpretable -- at the very least, less relevant to efficacy on actual seizures, and (2) we also believe the very clean AE/safety data of BHV-7000 raises the question of whether the drug is behaving like a potent anti-epileptic in the brain; we are skeptical of the GABA-selectivity thesis.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 10:26 AM
🔎 $PRAX Options Scan Update (04:26 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 1:46 AM
Enter: $PRAX Calls Strike Price: $280 Expiry Date: JAN 16 2026 Buy in Price: $18.90 - $22.00 Sell Price: $50.60 Profit : +130% (Turn every $1 into $2.30) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 8:27 PM
$PRAX RSI: 79.68, MACD: 25.8263 Vol: 39.04, MA20: 244.47, MA50: 204.41 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:14 PM
Actionable Trade Alert for $PRAX: Market Context: $PRAX is currently trading at $274.76, with a strong RSI of 79.68, indicating overbought conditions. The price is significantly above both the 30-day MA of 223.92 and the 50-day MA of 204.41, suggesting upward momentum but caution due to potential pullbacks. Directional Bias: Given the high RSI and proximity to the 60D high of 286.5, we anticipate a possible retracement before further upward movement. The 60D low of 50.31 provides a broad range for potential price action. Trade Plan: - Suggested Entry: $274.76 - Stop Loss: $250.00 (approximately 9% below entry) - Take Profit Targets: 1. $290.00 (5.5% gain) 2. $320.00 (16.4% gain) 3. $321.00 (17% gain) This plan allows for a strategic entry while managing risk effectively. Monitor RSI for any signs of reversal before entering. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
UnicornUptick
UnicornUptick Dec. 25 at 10:53 AM
$PRAX Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Execution reliability across quarters will determine whether confidence can compound. Any disconnect between guidance and results will be magnified by sentiment. Risk remains manageable if management converts plans into consistent outputs.
0 · Reply
NowakYandrey
NowakYandrey Dec. 24 at 5:13 PM
Here are my current positions: $SNDK $PRAX Looking great heading into Christmas
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 3:56 PM
Enter: $PRAX Calls Strike Price: $290 Expiry Date: JAN 16 2026 Buy in Price: $13.62 - $14.30 Sell Price: $20.84 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
R84877P
R84877P Dec. 22 at 10:39 PM
$PRAX Done and done ✅
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 22 at 10:10 PM
Enter: $PRAX Calls Strike Price: $280 Expiry Date: JAN 16 2026 Buy in Price: $17.81 - $19.40 Sell Price: $37.58 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 20 at 9:06 PM
Enter: $PRAX Calls Strike Price: $280 Expiry Date: JAN 16 2026 Buy in Price: $20.20 - $22.23 Sell Price: $45.79 Profit : +106% (Turn every $1 into $2.06) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
moric
moric Dec. 19 at 6:17 PM
$PRAX $PRAX Some analysts said that it is way undervalued and raised the price target to $750. But no buyers for even $275 . Why?
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:10 PM
$PRAX: Current market context shows a strong bullish trend with the last close at $269.26. The RSI at 73.59 indicates overbought conditions, suggesting a potential pullback. However, the price remains well above the 30-day MA of 210.19 and the 50-day MA of 186.59, indicating strength in the upward movement. Directional bias leans bullish, but caution is warranted due to the high RSI. Suggested entry is at $265, just below the current price to capture any potential pullback. Set a stop loss at $250 to manage risk. Take Profit Targets: 1. TP1: $275 (3.73% gain) 2. TP2: $285 (5.85% gain) 3. TP3: $315 (17% gain) Target 3 offers a significant ROI of over 17%. Monitor the price action closely, especially around the 60-day high of $282.99. Trade Plan: Enter at $265, stop at $250, with targets at $275, $285, and $315. Stay informed and trade wisely. https://privateprofiteers.com
0 · Reply
R84877P
R84877P Dec. 19 at 2:45 PM
$PRAX Let's go! $280!
0 · Reply
Bennybenito27
Bennybenito27 Dec. 18 at 7:30 AM
$CAPR $PLRZ $PRAX $SMX block all these
0 · Reply
timelesstrades
timelesstrades Dec. 17 at 8:27 PM
$PRAX hurry and offer shares!
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:55 AM
$PRAX is currently trading at $274.51, showing strong bullish momentum with an RSI of 79.22, indicating overbought conditions. The price is significantly above the 30-day moving average (MA30) of $203.57 and the 50-day moving average (MA50) of $178.01, reflecting a strong upward trend. The recent 60-day high of $282.99 suggests potential resistance at this level. Actionable Trade Alert: - Suggested Entry: $274.51 - Stop Loss: $250.00 (approx. 8.9% below entry) - Take Profit Targets: 1. $290.00 (5.6% gain) 2. $300.00 (9.3% gain) 3. $321.00 (17% gain) Given the current market context and momentum, a bullish bias is warranted. Monitor for price action around the 60D high for confirmation. Execute this plan to capitalize on potential upside while managing risk effectively. https://privateprofiteers.com
0 · Reply
R84877P
R84877P Dec. 16 at 2:59 PM
$PRAX Can't wait to see $300 before year end
0 · Reply
R84877P
R84877P Dec. 16 at 2:58 PM
0 · Reply
Quantumup
Quantumup Dec. 16 at 2:04 PM
H.C. Wainwright⬆️ $STOK's PT to $50 from $35 and reiterated at Buy $BIIB $UCBJY UCBJF $JAZZ $PRAX H.C. Wainwright said—Zorevunersen's rigorous propensity-weighted analysis reveals a clinically transformative ~82% seizure reduction and significant cognitive gains, substantially de-risking the Phase 3 EMPEROR study which is powered for far more modest improvements. With strong KOL validation supporting its use in severe patients despite safety signals, and new data expanding the addressable market to "Atypical Dravet," Stoke offers a scientifically validated "root cause" opportunity with significant regulatory upside. Therefore, given the data, the potential of zorevunersen for atypical Dravet patients, and the KOL validation, we revisited our PoS assumptions, and our penetration assumptions, which increases our PT from $35 to $50.
0 · Reply
timelesstrades
timelesstrades Dec. 15 at 8:16 PM
$PRAX over valued with only 20mill shares! Expect dilution boys!
1 · Reply
Creisi
Creisi Dec. 15 at 6:30 PM
$MLTX $PRAX Yes PRAX is not a clinical biopharma with the weight of the entire company hanging on this press release. MLTX are conducting their first pre-BLA Type B FDA meeting. If it were me, and it was in the past, I wouldn't be saying dog shit until Legal reviewed the PR release and approved it. These are the reasons you have a business lawyer either on staff or retainer. My guess it could come very late today or by Friday at the latest. Suggesting how soon it comes to infer good or bad news is completely ridiculous. 'How soon it comes means nothing because we have no historical reference on how MLTX Board prefer to handle such releases.'
1 · Reply